Patient Portal

Joel Picus, MD

Professor, Medicine
Division of Oncology - Medical Oncology
Section, Medical and Molecular Oncology

Specialty Areas

Oncology
Hematology
Gastrointestinal Oncology
Hepatobiliary Cancer
Colon and Rectal Cancer
Genitourinary Oncology
Pancreatic Cancer

Board Certifications

Hematology
Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-9281
Fax: 314-362-7086

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Office Phone: 314 747 1171

Education

Education

Fellowship: Hematology and Oncology, Cancer Research Institute, University of California, San Francisco, CA 1991
Residency: Internal Medicine, Duke University Medical Center 1987
Medical Degree: Harvard Medical School, Boston, MA 1984
B.S.: Electrical Engineering, University of Illinois, Urbana, IL 1979
B.A.: Biology, University of Illinois, Urbana, IL 1979

Publication & Research

Publication & Research

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK
Br J Cancer. 2018 May 16; doi: 10.1038/s41416-018-0087-9.

PMID:
    29765151
    [PubMed - as supplied by publisher]
Related citations


Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
Eur J Cancer. 2018 May; 94115-125. doi: 10.1016/j.ejca.2018.02.012.

PMID:
    29550566
    [PubMed - in process]
Related citations


Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C
Eur Urol. 2018 Jun; 73(6)847-855. doi: 10.1016/j.eururo.2018.02.001.

PMID:
    29475737
    [PubMed - in process]
Related citations


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ
J Clin Oncol. 2018 Apr 10; 36(11)1080-1087. doi: 10.1200/JCO.2017.75.3657.

PMID:
    29384722
    [PubMed - in process]
Related citations


Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ, ECOG-ACRIN 3805 Investigators.
J Clin Oncol. 2018 Feb 1; 36(4)376-382. doi: 10.1200/JCO.2017.75.3921.

PMID:
    29261442
    [PubMed - in process]
Related citations


Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ
J Clin Oncol. 2017 Feb 20; 35(6)591-597. doi: 10.1200/JCO.2016.70.7398.

PMID:
    28199818
    [PubMed - indexed for MEDLINE]
Related citations


Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N
Oncotarget. 2017 May 23; 8(21)35326-35338. doi: 10.18632/oncotarget.15108.

PMID:
    28186961
    [PubMed - indexed for MEDLINE]
Related citations


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators.
N Engl J Med. 2016 Nov 10; 375(19)1834-1844.

PMID:
    27633186
    [PubMed - indexed for MEDLINE]
Related citations


Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH
Support Care Cancer. 2016 Jul; 24(7)2837-42. doi: 10.1007/s00520-016-3100-y.

PMID:
    26838019
    [PubMed - indexed for MEDLINE]
Related citations


Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ
Lancet Oncol. 2016 Mar; 17(3)378-88. doi: 10.1016/S1470-2045(15)00515-X.

PMID:
    26794930
    [PubMed - indexed for MEDLINE]
Related citations


Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.
Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, Trull L, Belanger S, Desai M, Mahmood S, Mendell J, Welch MJ, Siegel BA
Mol Imaging Biol. 2016 Jun; 18(3)446-53. doi: 10.1007/s11307-015-0912-y.

PMID:
    26567113
    [PubMed - indexed for MEDLINE]
Related citations


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS
N Engl J Med. 2015 Aug 20; 373(8)737-46. doi: 10.1056/NEJMoa1503747.

PMID:
    26244877
    [PubMed - indexed for MEDLINE]
Related citations


A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR
HPB (Oxford). 2015 Jul; 17(7)587-93. doi: 10.1111/hpb.12413.

PMID:
    25800066
    [PubMed - indexed for MEDLINE]
Related citations


Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C
Cancer Chemother Pharmacol. 2015 Mar; 75(3)485-93. doi: 10.1007/s00280-014-2668-5.

PMID:
    25556030
    [PubMed - indexed for MEDLINE]
Related citations


Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC
PLoS One. 2014; 9(9)e107424. doi: 10.1371/journal.pone.0107424.

PMID:
    25232828
    [PubMed - indexed for MEDLINE]
Related citations


A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.
Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
Cancer Chemother Pharmacol. 2014 Aug; 74(2)419-26. doi: 10.1007/s00280-014-2493-x.

PMID:
    24916546
    [PubMed - indexed for MEDLINE]
Related citations


Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P
Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4)829-36. doi: 10.1016/j.ijrobp.2013.12.028.

PMID:
    24606849
    [PubMed - indexed for MEDLINE]
Related citations


Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, COU-AA-301 Investigators.
Eur J Cancer. 2013 Nov; 49(17)3648-57. doi: 10.1016/j.ejca.2013.07.144.

PMID:
    23973186
    [PubMed - indexed for MEDLINE]
Related citations


A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U
Clin Genitourin Cancer. 2013 Dec; 11(4)477-83. doi: 10.1016/j.clgc.2013.05.005.

PMID:
    23891158
    [PubMed - indexed for MEDLINE]
Related citations


A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G
Cancer Chemother Pharmacol. 2013 Sep; 72(3)537-44. doi: 10.1007/s00280-013-2224-8.

PMID:
    23820963
    [PubMed - indexed for MEDLINE]
Related citations